This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crowley, N. J. Articles by Seigler, H. F. Search for Related Content PubMed PubMed Citation Articles by Crowley, N. J. Articles by Seigler, H. F.

Generation of Human Autologous Melanoma-specific Cytotoxic T-Cells Using HLA-A2-matched Allogeneic Melanomas¹

Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710

Autologous tumor-specific cytotoxic T-lymphocytes (CTLs), generated by repeated stimulation with autologous melanoma and expanded in interleukin 2, are major histocompatibility complex restricted. These CTLs recognize a common tumor-associated antigen in the presence of HLA class I determinants, suggesting that allogeneic melanomas which express the restricting HLA-A region antigen could substitute for the autologous tumor in the generation of CTLs. This was investigated in the HLA-A2 system. Four T-cell lines were established by stimulation of lymphocytes with either autologous tumor or an HLA-A2-matched allogeneic melanoma. Allogeneic stimulated CTLs specifically lysed the autologous tumor and demonstrated an identical pattern of HLA-A2 restriction, when compared to the autologous stimulated CTLs. Lysis by the allogeneic stimulated CTLs was blocked by a monoclonal antibody to HLA class I antigens; lysis was also inhibited by both autologous tumor or HLA-A2 allogeneic melanomas when evaluated in cold target competition studies. The allogeneic stimulated CTLs proliferated in response to both autologous tumor and HLA-A2 melanomas, but not in response to HLA-A2 nonmelanomas. By phenotypic analysis these CTLs were CD3+ and predominantly CD8+ cells. We conclude that autologous tumor-specific CTLs can be generated using HLA-A region-matched allogeneic melanomas for stimulation. Since established, HLA-typed melanoma tumor lines can be used in the absence of autologous tumor; this procedure can be applied clinically to a broad patient population and may prove useful in the adoptive immunotherapy of melanoma.

¹ This work is supported in part by NIH Grant 2-P01-CA-32672-05A1, Veterans Administration Project 821, and the DuPont Corporation, Wilmington, DE.

² To whom requests for reprints should be addressed, at Box 3966, Duke University Medical Center, Durham, NC 27710.

Received 6/29/89. Revised 10/12/89. Accepted 10/30/89.

This article has been cited by other articles:

				T. Zhang, B. A. Lemoi, and C. L. Sentman Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy Blood, September 1, 2005; 106(5): 1544 - 1551. [Abstract] [Full Text] [PDF]

				J. J. Roszkowski, G. E. Lyons, W. M. Kast, C. Yee, K. Van Besien, and M. I. Nishimura Simultaneous Generation of CD8+ and CD4+ Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell Receptor Cancer Res., February 15, 2005; 65(4): 1570 - 1576. [Abstract] [Full Text] [PDF]

				M. Salio, D. Shepherd, P. R. Dunbar, M. Palmowski, K. Murphy, L. Wu, and V. Cerundolo Mature Dendritic Cells Prime Functionally Superior Melan-A-Specific CD8+ Lymphocytes as Compared with Nonprofessional APC J. Immunol., August 1, 2001; 167(3): 1188 - 1197. [Abstract] [Full Text] [PDF]

				S. Yang, D. Kittlesen, C. L. Slingluff Jr., C. E. Vervaert, H. F. Seigler, and T. L. Darrow Dendritic Cells Infected with a Vaccinia Vector Carrying the Human gp100 Gene Simultaneously Present Multiple Specificities and Elicit High-Affinity T Cells Reactive to Multiple Epitopes and Restricted by HLA-A2 and -A3 J. Immunol., April 15, 2000; 164(8): 4204 - 4211. [Abstract] [Full Text] [PDF]

				K. Yamazaki, G. Spruill, J. Rhoderick, J. Spielman, N. Savaraj, and E. R. Podack Small Cell Lung Carcinomas Express Shared and Private Tumor Antigens Presented by HLA-A1 or HLA-A2 Cancer Res., September 1, 1999; 59(18): 4642 - 4650. [Abstract] [Full Text] [PDF]

				R. E. Sobol, D. L. Shawler, C. Carson, C. Van Beveren, D. Mercola, H. Fakhrai, M. A. Garrett, R. Barone, P. Goldfarb, R. M. Bartholomew, et al. Interleukin 2 Gene Therapy of Colorectal Carcinoma with Autologous Irradiated Tumor Cells and GeneticallyEngineered Fibroblasts: A Phase I Study Clin. Cancer Res., September 1, 1999; 5(9): 2359 - 2365. [Abstract] [Full Text] [PDF]

				T. M. Clay, M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura Efficient Transfer of a Tumor Antigen-Reactive TCR to Human Peripheral Blood Lymphocytes Confers Anti-Tumor Reactivity J. Immunol., July 1, 1999; 163(1): 507 - 513. [Abstract] [Full Text] [PDF]

				P van der Bruggen, C Traversari, P Chomez, C Lurquin, E De Plaen, B Van den Eynde, A Knuth, and T Boon A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science, December 13, 1991; 254(5038): 1643 - 1647. [Abstract] [PDF]